The p53 Tumour Suppressor Protein

Biotechnology and Genetic Engineering Reviews

Volumn 17, Issue 1, 2000, Pages 179-212

  Hickman, Emma S ^a   Helin, Kristian ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR SUPPRESSOR PROTEINS;

PROTEINS;

APC PROTEIN; PROTEIN P53;

CANCER; CANCER INHIBITION; CARCINOGENESIS; CELL ACTIVITY; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; DNA DAMAGE; DNA REPLICATION; GENE MUTATION; GENE THERAPY; GENETIC ANALYSIS; PROTEIN EXPRESSION; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0034487589     PISSN: 02648725     EISSN: 20465556     Source Type: Journal    
DOI: 10.1080/02648725.2000.10647992     Document Type: Article

References (225)

1. Agami, R., Blandino, G., Oren, M. and Shaul, Y. (1999). Interaction of c-Abl and p73a and their collaboration to induce apoptosis. Nature 399, 809-813
2. Agarwal, M. L., Agarwal, A., Taylor, W. R. and Stark, G. R. (1995). p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proceedings of the National Academy of Sciences of the United States of America 92, 8493-8497
3. An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V. and Neckers, L. M. (1998). Stabilization of wild-type p53 by hypoxia-inducible factor la. Nature 392, 405-408
4. Attardi, L. D., Lowe, S. W., Brugarolas, J. and Jacks, T. (1996). Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO Journal 15, 3693-3701
5. Avantaggiati, M. L., Ogryzko, V., Gardner, K., Giordano, A., Levine, A. J. and Kelly, K. (1997). Recruitment of p3Q0/CBP in p53 dependent signal pathways. Cell 89, 1175-1184
6. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V. and Vogelstein, B. (1990). Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249, 912-915
7. Banin, S., Moyal, L., Khostravi, R., Shieh, S. -Y., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Frives, C., Shiloh, Y. and Ziv, Y. (1998). Enhanced phosphoiy-lation of p53 by ATM in response to DNA damage. Science 281, 1674-1677
8. Barak, Y., Juven, T., Haffner, R. and Oren, M. (1993). Mdm2 expression is induced by wild type p53 activity. EMBO Journal 12, 461-468
9. Bargonetti, J., Manfredi, J. J., Chen, X., Marshak, D. R. and Prives, C. (1993). A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes & Development 7, 2565-2574
10. Bates, S., Rowan, S. and Vousden, K. H. (1996). Characterisation of human cyclin G1 and G2: DNA damage inducible genes. Oncogene 13, 1103-1109
11. Bates, S., Phillips, A. C., Clark, P. A., Stott, F., Peters, G., Ludwig, R. L. and Vousden, K. H. (1998). E2F-1 regulation of pl4AR,: links pRB and p53. Nature 395, 124-125
12. Benedict, W. F., Murphree, A. L., Banerjee, A., Spina, C. A., Sparkes, M. C. and Sparkes, R. S. (1983). Patient with chromosome 13 deletion: evidence that the retinoblastoma gene is a recessive cancer gene. Science 219, 973-975
13. Bennett, M., Macdonald, K., Chan, S. -W., Luzio, J. P., Simari, R. and Weissberg, P. (1998). Cell surface rafficking of Fas: A rapid mechanism of p53-mediated apoptosis. Science 282, 290-293
14. Biernat, W., Kleihues, P., Yonekawa, Y. and Ohgaki, H. (1997). Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. Journal of Neuropathology and Experimental Neurology 56, 180-185
15. Blagosklonny, M. V. and El-Deiry, W. S. (1996). In vitro evaluation of a p53-expressing adenovirus as an anticancer drug. International Journal of Cancer 67, 386-392
16. Blattner, C., Tobiasch, E., Lstfen, M., Rahmsdouf, H. J. and Herrlich, P. (1999). DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene 18, 1723-1732
17. Brachman, D. G., Beckett, M., Graves, D., Haraf, D., Vokes, E. and Weichselbaum, R. R. (1993). p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Research 53, 3667-3669
18. Brady, H. J., Salomons, G. S., Bobelduk, R. C. and Burns, A. J. (1996). T ceils from bax aipha transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53. EMBO Journal 15, 1221-1230
19. Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T. and Hannon, G. J. (1995). Radiation-induced cell cycle arrest compromised by p2i deficiency Nature 377, 552-557
20. Buchhop, S., Gibson, M. K., Wang, X. W., Wagner, P., Sturzbecher, H. W. and Harris, C. C. (1997). Interaction of p53 with the human Rad51 protein. Nucleic Acids Research 25, 3868-3874
21. Buckbinder, L., Talbott, R., Velasco-Miguel, S., Takenaka, I., Faha, B., Seizinger, B. R. and Kley, N. (1995). Induction of the growth inhibitor IGF-binding protein 3 byp53 Nature 377, 646-649
22. Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W. and Vogelstein, B. (1998). Requirement forp53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497-1501
23. Buttitta, F., Marchetti, A., Gadduci, A., Pellegrini, S., Morgantj, M., Carnicelli, V., Cosío, S., Gagetti, O., Genazzanui, A. R. and Bevilaqua, G. (1997). p53 alterations are predictive of chemoresistance and agressiveness in ovarian carcinomas: a molecular and immunohistochemical study. British Journal of Cancer 75, 230-235
24. Caelles, C., Helmberg, A. and Karin, M. (1994). p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370, 220-223
25. Canman, C. E., Wolff, A. C., Chen, C. Y., Fornace, A. J., and Kastan, M. B. (1994). The p53-dependent Gl cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Research 54, 5054-5058
26. Canman, C. E., Lim, D. S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B. and Sjuciano, D. D. (1998). Activation of the ATM kinase by ionising radiation and phosphorylation of p53. Science 281, 1677-1679
27. Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R. and Soltoff, S. (1991). Oncogenes and signal transduction. Cell 64, 281-302
28. Cavenee, W. K., Dryja, T. P., Phillips, R. A., Benedict, W. F., Godbout, R., Gallie, B. L., Murphree, A. L., Strong, L. C. and Sparkes, R. S. (1983). Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305, 779-784
29. Chen, X., Farmer, G., Zhu, H., Prywes, R. and Prives, C. (1993). Cooperative DNA binding of p53 with TFÍFD (TBP): a possible mechanism for transcriptional activation. Genes & Development 7, 1837-1849
30. Chernov, M. V., Ramana, C. V., Adler, V. V. and Stark, G. R. (1998). Stabilization and activation of p53 are regulated independently by different phosphorylation events. Proceedings of the National Academy of Sciences of the United States of America 95, 2284-2289
31. Cho, Y., Gorina, S., Jeffrey, P. D. and Pavletich, N. P. (1994). Crystal structure of a p53 tumour suppressor-DNA complex: understanding tumourigenic mutations. Science 265, 346-355
32. Chresta, C. M., Masters, J. R. W. and Hickman, J. A. (1996). Hypersensitivity of human testicular tumours to etoposide-induced apoptosis is associated with functional p53 and a high bax:bcl-2 ratio. Cancer Research 56, 1834-1841
33. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L. and Wylue, A. H. (1993). Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849-852
34. Clarke, A. R., Howard, L. A., Harrison, Dj. and Winton, D. J. (1997). p53, mutation frequency and apoptosis in the murine small intestine. Oncogene 14, 2015-2018
35. Crook, T., Marston, N. J., Sara, E. A. and Vousden, K. H. (1994). Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79, 817-827
36. Cross, S. M., Sanchez, C. A., Morgan, C. A., Schimke, M. K., Ramel, S., Idzerda, R. L., Raskind, W. H. and Reid, B, J. (1995). A p53-dependent mouse spindle checkpoint. Science 267, 1353-1356
37. Debbas, M. and White, E. (1993). Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes & Development 7, 546-554
38. Delaurenzini, V., Costanzo, A., Barcarou, D., Terrinoni, A., Falco, M., Annicchiarico-Petruzzelli, M., Levrero, M. and Melino, G. (1998). Two new p73 splice variants g and d, with different transcriptional activity. Journal of Experimental Medicine 188, 1763-1768
39. Deleo, A. B., Jay, G., Appella, E., Dubois, G. C., Law, L. W. and Old, L. J. (1979). Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proceedings of the National Academy of Sciences of the United States of America 76, 2420-2424
40. Deng, C., Zhang, P., Harper, J. W., Elledge, Sj. and Leder, P. (1995). Mice lacking p2i wafi/cipi underg0 normal development but are defective in G1 checkpoint control. Cell 82, 675-684
41. De Stanchina, E., Mccurrach, M. E., Zindy, F., Sheih, S. -Y., Ferbeyre, G., Samuelson, A. V., Prives, C., Roussel, M. F., Sherr, C. J. and Lowe, S. W. (1998). E1A signalling to p53 involves the p 19ARFtumor suppressor. Genes Development 12, 2434-2442
42. Dileonardo, A., Khan, S. H., Linke, S. P., Greco, V., Seidita, G. and Wahl, G. M. (1997). DNA replication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRB function. Cancer Research 57, 1013-1019
43. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C. and Levine, Aj. (1993). Gain of function mutations in p53. Nature Genetics 4, 42-46
44. Donehower, L. A., Harvey, M., Slagle, B. L., Mcarthur, M. J., Montgomery, C. A., Butel, J. S. and Bradley, A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221
45. Dryja, T. P., Rapaport, J. M., Joyce, J. M. and Petersen, R. A. (1986). Molecular detection of deletions involving band 14q of chromosome 13 in retinoblastoma. Proceedings of the National Academy of Sciences of the United States of America 83, 7391-7394
46. Duuc, V., Kaufmann, W. K., Wilson, S. J., Tlsty, T. D., Lees, E., Harper, J. W., Elledge, S. J. and Reed, S. L. (1994). p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest Cell 76, 1013-1023
47. El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Klnzler, K. W. and Vogelstein, B. (1992). Definition of a consensus binding site for p53. Nature Genetics 1, 45-49
48. El-Deiry, W. S., Torino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825
49. Eliyahu, D., Raz, A., Gruss, P., Givol, D. and Oren, M. (1984). Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 312, 646-649
50. Enari, M., Hug, H. and Nagata, S. (1995). Involvement of an ICE-fike protease in Fasmediated apoptosis. Nature 375, 78-81
51. Fan, S., El-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J., Magrath, I., Kohn, K. W. and O'Connor, P. M. (1994). p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Research 54, 5824-5830
52. Fan, S., Smith, M. L., Rivet, D. J., Duba, D., Zahn, Q., Kohn, K. W., Fornace, A. J. and O'Connor, P. M. (1995). Disruption of p53 function sensitises breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Research 55, 1649-1654
53. Fields, S. and Jang, S. K. (1990). Presence of a potent transcriptional activating sequence in the p53 protein. Science 249, 1046-1049
54. Finlay, C. A., Hinds, P. W. and Levine, A. J. (1989). The p53 proto-oncogene can act as a suppressor of transformation. Cell 57, 1083-1093
55. Fiscella, M., Zhang, H., Fan, S., Sakaguchi, K., Shen, S., Mercer, W. E., Vande Woude, G. F., O'Connor, P. M. and Appella, E. (1997). Wipl, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proceedings of the National Academy of Sciences of the United States of America 94, 6048-6053
56. Fritsche, M., Haessler, C. and Brandner, G. (1993). Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8, 307-318
57. Fuchs, S. Y., Alder, V., Pincus, M. and Ronai, Z. (1998). MEKK/JNK signalling stabilizes and activates p53. Proceedings of the National Academy of Sciences of the United States of America 95, 10541-10546
58. Fujiwara, T., Grimm, E. A., Mukhophadhyay, T., Zhang, W. W., Owen-Schaub, L. B. and Roth, J. A. (1994). Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild type p53 gene. Cancer Research 54, 2287-2291
59. Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S. and Vande Woude, G. F. (1996). Abnormal centrosome amplification in the absence of p53. Science 271, 1744-1747
60. Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E. and Shay, J. W. (1992). A transcriptionally active DNA-binding site for human p53 protein complexes. Molecular and Cellular Biology 12, 2866-2871
61. Gallardo, D., Drazan, K. E. and Mcbride, W. H. (1996). Adenovirus-based transfer of wild-type p53 gene increases ovarian tumour radiosensitivity. Cancer Research 56, 4891-4893
62. Garkavtsev, I., Grigorian, I., Ossovskaya, V. S., Chernov, M. V., Chumakov, P. M. and Gudkov, A. V. (1998). The candidate tumour suppressor p33INGl cooperates with p53 in cell growth control. Nature 391, 295-298
63. Ginsberg, D., Mechta, F., Yaniv, M. and Oren, M. (1991). Wild-type p53 can down-modulaie the activity of various promoters. Proceedings of the National Academy of Sciences of the United States of America 88, 9979-9983
64. Gong, J. G., Costanzo, A., Yang, H. -Q., Melino, G., Kaelin, W. G., Levrero, M. and Wang, J. Y. J. (1999). The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399, 806-809
65. Gorina, S. and Pavletich, N. P. (1996). Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274, 1001-1005
66. Gottlieb, E., Haffner R., Von-Ruden, T., Wagner, E. F. and Oren, M. (1994). Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO Journal 13, 1368-1374
67. Graeber, T. G., Peterson, J. F., Tsai, M., Fornace, A. J. and Giaccia, A. J. (1994). Hypoxia induces the accumulation of p53 protein, but the activation of a G1 -phase checkpoint by low oxygen conditions is independent of p53 status. Molecular and Cellular Biology 14. 6264-6277
68. Greenblatt, M. S., Bennett, W. P., Hollstein, M. and Harris, C. C. (1994). Mutations in the p53 tumor suppressor gene: Clues to cancer eitology and molecular pathogenesis. Cancer Research 54, 4855-4878
69. Gu, W. and Roeder, R. G. (1997). Activation of p53 sequence specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606
70. Gu, W., Shi, X. -L. and Roeder, R. G. (1997). Synergistic activation of transcription by CBP and p53. Nature 387, 819-822
71. Gualberto, A., Aldape, K., Kozakiewicz, K. and Tlsty, T. D. (1998). An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proceedings of the National Academy of Sciences of the United States of America 95, 5166-5171
72. Haapajarvi, T., Pitkanen, K., Tsubari, M. and Laiho, M. (1997). p53 transactivation and protein accumulation are independently regulated by UV light in different phases of the cell cycle. Molecular and Cellular Biology 17, 3074-3080
73. Hall, P. A., Mckee, P. H., Menage, H. P., Dover, R. and Lane, D. P. (1993). High levels of p53 protein in UV-irradiated normal human skin. Oncogene 8, 203-207
74. Hanawalt, P. C. (1994). Transcription-coupled repair and human disease. Science 266, 1957-1958
75. Hahn, W. C., Counter, C. M., Lundberg, A. S., Beuersbergen, R. L., Brooks, M. W. and Weinberg, R. A. (1999). Creation of human tumour cells with defined genetic elements. Nature 400, 464-468
76. Hann, B. C. and Lane, D. P. (1995). The dominating effect of mutant p53. Nature Genetics 9, 221-222
77. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. and Elledge, S. J. (1993). The p21 CDK-interacting protein Cip 1 is a potent inhibitor of G1 cyclin dependent kinases. Cell 75, 805-816
78. Haupt, Y., Rowan, S., Shauuan, E., Vousden, K. H. and Oren, M. (1995). Induction of apoptosis in HeLa cells by transactivation deficient p53. Genes & Development 9, 2170-2183
79. Haupt, Y., Maya, R., Kazaz, A. and Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299
80. Hawkins, D. S., Demers, G. W. and Galloway, D. A. (1996). Inactivation of p53 enhances sensitivity to multiple chemotherapeutic drugs. Cancer Research 56, 892-898
81. Hermekjng, H. and Elck, D. (1994). Mediation of c-myc induced apoptosis by p53. Science 265, 2091-2093
82. Hermeking, H., Lengauer, C., Polyak, K., He, T. C., Zhang, L., Thiagaungam, S., Kinzler, K. W. and Vogelstein, B. (1997). 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Molecules and Cells 1, 3-11
83. Herskowitz, I. (1987). Functional inactivation of genes by dominant negative mutations. Nature 329, 219-222
84. Hiebert, S. W., Packham, G., Strom, D. K., Haffner, R., Oren, M., Zambeth, G. and Cleveland, J. L. (1995). E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Molecidar and Cellular Biology 15, 6864-6874
85. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C. (1991). p53 mutations in human cancers. Science 253, 49-53
86. Holmberg, C., Helsn, K., Sehested, M. and Karlstrom, O. (1998). E2F-1-induced p53-independent apoptosis in transgenic mice. Oncogene 17, 143-155
87. Hupp, T. R. and Lane, D. P. (1994). Ailosteric activation of latent p53 teramers. Current Biology 4, 865-875
88. Hupp, T. R., Meek, D. W., Midgley, C. A. and Lane, D. P. (1993). Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Research 21, 3167-3174
89. Jayaraman, L. and Prives, C. (1995). Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81, 1021-1029
90. Jayaraman, L., Murthy, K. J., Zhu, C., Curran, T., Xanthoudakis, S. and Prives, C. (1997). Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes & Development 11, 558-570
91. Jeffrey, P. D., Gorina, S. and Pavletich, N. P, (1995). Crystal structure of the tetramerization domain of the p53 tumour suppressor at 1. 7 angstroms. Science 267, 1498-1502
92. Jimenez, G. S., Bryntesson, F., Torres-Arzayus, M. I., Priestley, A., Beeche, M., Saito, S., Sakaguchi, K., Appella, E., Jeggo, P. A., Taccioli, G. E., Wahl, G. M. and Hubank, M. (1999). DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage. Nature 400, 81-83
93. Jones, S. N., Roe, A. E., Donehower, L. A. and Bradley, A. (1995). Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378, 206-208
94. Jost, C. A., Martin, M. C. and Kaelin, W. G., (1997). p73 is a human p53-related protein that can induce apoptosis. Nature 389, 191-194
95. Juven, T., Barak, Y., Zaubermann, A., George, D. and Oren, M. (1993). Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8, 3411-3416
96. Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J. -C., Valent, A., Minty, A., Chalon, P., Lelias, J. -M., Dumont, X., Ferrara, P., Mckeon, F. and Caput, D, (1997). Monoallelically expressed gene related to p53 at lp36, a region frequently deleted in neuroblasoma and other human cancers. Cell 90, 809-819
97. Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G. and Sherr, C. J. (1997). Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product pl9AR,:. Cell 91, 649-659
98. Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F. and Sherr, C. J. (1998). Functional and physical interactions of the ARF tumour suppressor with p53 and Mdm2. Proceedings of the National Academy of Sciences of the United States of America 95, 8292-8297
99. Kapoor, M. and Lozano, G. (1998). Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proceedings of the National Academy of Sciences of the United States of America 95, 2834-2837
100. Kastan, M. B., Onyekwere, O., Sldransky, D., Vogelstein, B. and Craig, R. W. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Research 51, 6304-6311
101. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B. and Fornace, A. J.,. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71, 587-597
102. Kaufmann, W. and Paules, R. S. (1996). DNA damage and cell cycle checkpoints. FASEB Journal 10, 238-247
103. Kern, S. E., Kinzler, K. W., Baker, S. J., Bruskin, A., Jarosz, D., Friedman, P., Prives, C. and Vogelstein, B. (1991). Identification of p53 as a sequence-specific DNA-binding protein. Science 252, 1708-1711
104. Khan, S. H, and Wahl, G. M. (1998). p53 and pRB prevent replication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Research 58, 396-400
105. Khanna, K. K. and Lavin, M. F. (1993). Ionizing radiation and UV induction of p53 protein by different pathways in ataxia telangiectasia cells. Oncogene 8, 3307-3312
106. Kharbanda, S., Pandey, P., Schofield, L., Israels, S., Roncinske, R., Yoshida, K., Bharti, A., Yuan, Z. M., Saxena, S., Weichselbaum, R., Naun, C. and Kufe, D (1997). Roie for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proceedings of the National Academy of Sciences of the United States of America 94, 6939-6942
107. Kluck, R. M., Bossy-Wetzel, E., Green, D. R. and Newmeyer, D. D. (1997). The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275, 1132-1136
108. Knippschild, U., Milne, D. M., Campbell, L. E., Demaggjo, A. J., Christenson, E., Hoekstra, M. F. and Meek, D. W. (1997). p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase I and enhances the level of casein kinase I delta in response to topoisomerase directed drugs. Oncogene 15, 1727-1736
109. Knudson, A. G. J. (1971). Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Sciences of the United States of America 68, 820-823
110. Ko, L. J., Shieh, S. Y., Chen, X., Jayaraman, L., Tamai, K., Taya, Y., Prives, C. and Pan, Z. Q. (1997). p53 is phosphorylated by CDK7-cyclin H in a p36MATl-dependent manner. Molecular and Cellular Biology 17, 7220-7229
111. Kovalev, S., Marchenko, N., Swendeman, S., Laquaglia, M. and Moll, U. M. (1998). Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastomas and cel! lines. Cell Growth & Differentiation 9, 897-903
112. Kraiss, S. A., Quaiser, A., Oren, M. and Montenarh, M. (1988). Oligomerization of the oncoprotein p53. Journal of Virology 62, 4737-4744
113. Krek, W. and Nigg, E. A. (1991). Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLa cells: evidence for a double block to p34cdc2 kinase activation in vertebrates. EMBO Journal 10, 3331-3341
114. Kubbutat, M. H., Jones, S. N. and Vousden, K. H. (1997). Regulation of p53 stability by MdmZ Nature 387, 229-303
115. Lane, D. and Benchimol, S. (1990). p53 oncogene or antioncogene. Genes & Development 4, 1-8
116. Lane, D. and Crawford, L. V. (1979). T antigen is bound to a host protein in SV40-transformed cells. Nature 278, 261-263
117. Lanni, J. S. and Jacks, T. (1998). Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Molecular and Cellular Biology 18, 1055-1064
118. Lee, J. M. and Bernstein, A. (1993). p53 mutations increase resistance to ionising radiation. Proceedings of the National Academy of Sciences of the United States of America 90, 5742-5746
119. Lees-Miller, S. P., Sakaguchi, K., Ullrich, S. J., Appella, E. and Anderson, C. W. (1992). Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Molecular and Cellular Biology 12, 5041-5049
120. Levine, A. J., Momand, J. and Finlay, C. A. (1991). The p53 tumour suppressor gene. Nature 351, 453-456
121. Linke, S. P., Clarkin, K. C., Dileonardo, A., Tsou, A, and Wahl, G. M. (1996). A reversible, p53 dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes & Development 10, 934-947
122. Llnzer, D. H. and Levine, A. J. (1979). Characterization of a 54K dalton cellular SV40 tumor antigen present in S V40-transfonned cells and uninfected embryonal carcinoma cells. Cell 17, 43-52
123. Liu, X., Kim, C. N., Yang, J., Jemmerson, R. and Wang, X. (1996). Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86, 147-157
124. Lowe, S. W. and Ruley, H. E. (1993). Stabilization of the p53 tumour suppressor is induced by adenovirus 5 El A and accompanies apoptosis. Genes & Development 7, 535-545
125. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A. and Jacks, T. (1993a). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849
126. Lowe, S. W., Ruley, H. E., Jacks, T. and Housman, D. E. (1993b). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967
127. Lu, H. and Levine, A. J. (1995). Human TAF-31 is a transcriptional coactivator of the p53 protein. Proceedings of the National Academy of Sciences of the United States of America 92, 5154-5158
128. Lu, H., Fisher, R. P. and Levine, A. J. (1997). The CDK-cycH-p36 complex of transcription factor 11 H phosphorylates p53 and enhances its sequence-specific DNA binding activity in vitro. Molecular and Cellular Biology 17, 5923-5934
129. Lu, H., Taya, Y., Ikeda, M. and Levine, À. J. (1998). Ultraviolet radiation but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 at serine-38. Proceedings of the National Academy of Sciences of the United States of America 95, 6399-6402
130. Macleod, K. F., Hu, Y. and Jacks, T. (1996). Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system. EMBO Journal 15, 6178-6188
131. Mai, M., Huang, H., Reed, C., Qian, C., Smith, J. S., Alderete, B., Jenkins, R., Smith, D. L. and Liu, W. (1998a). Genomic organisation and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletion. Genomics 51, 359-363
132. Mai, M., Yokomizo, A., Qian, C., Yang, P., Tindall, D. J., Smith, D. L. and Liu, W. (1998b). Activation of p73 silent allele in lung cancer. Cancer Research 58, 2347-2349
133. Maity, A., Mckenna, W. G. and Muschel, R. J. (1995). Evidence for post-transcriptional regulation of cyclin B1 mRNA in the cell cycle and following irradiation in HeLa cells. EMBO Journal 14, 603-609
134. Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A. and Friend, S. H, (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238
135. Malzman, W. and Czyzyk, L. (1984). UV radiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Molecular and Cellular Biology 4, 1689-1694
136. Marin, M. C., Jost, C. A., Decaprio, J. A., Caput, D. and Kaelin, W. G., (1998). Viral oncoproteins discriminate between p53 and the p53 homolog p73. Molecular and Cellular Biology 18, 6316-6324
137. Mccormick, F. and Harlow, E. (1980). Association of a murine 53, 000-dalton phosphoprotein with simian virus 40 large-T antigen in transformed cells. Journal of Virology 34, 213-224
138. Mccoy, M., Stavridi, E. S., Waterman, J. L., Opella, S. J. and Halazonetis, T. D. (1997). Hydrophobic stde-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain. EMBO Journal 16, 6230-6236
139. Mcilwrath, A. J., Vasey, P. A., Ross, G. M. and Brown, R. (1994). Cell cycle arrests and radiosensitivity of human tumour cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Research 54, 3718-3722
140. Mclure, K. G. and Lee, P. W. (1999). p53 DNA binding can be modulated by factors that alter the conformational equilibrium. EM BO Journal 18, 763-770
141. Merajver, S. D., Pham, T. M., Caduff, R. F., Chen, M., Poy, E. L., Cooney, K. A., Weber, B. L., Collins, F. S., Johnston, C. and Frank, T. S, (1995). Somatic mutations in the BRCAi gene in sporadic ovarian tumours. Nature Genetics 9, 439-443
142. Mills, A. A., Zheng, B., Wang, X. -J., Vogel, H., Roop, D. R. and Bradley, A. (1999). p63 is a p53 homologue required for limb and epidennal morphogenesis. Nature 398, 708-713
143. Milne, D. M., Campbell, L. E., Campbell, D. G. and Meek, D. W. (1995). p53 is phosphory-lated in vitro and in vivo by an ultraviolet radiation induced protein kinase characteristic of the c-jun kinase, JNK1. Journal of Biological Chemistry 270, 5511-5518
144. Milner, J., Metcalf, E. A. and Cook, A. C. (1991). Tumor suppressor p53: analysis of wildtype and mutant p53 complexes. Molecular and Cellular Biology 11, 12-19
145. Miyashita, T. and Reed, J. C. (1995). Tumour suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293-299
146. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B. and Reed, J. C. (1994). Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9, 1799-1805
147. Momand, J., Zambetti, G. P., Olson, D. C., George, D. and Levine, A. J. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245
148. Montes DeOcaLuna, R., Wagner, D. S, and Lozano, G. (1995). Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203-206
149. Nigro, J. M., Aldape, S. M., Hess, S. M. and Tlsty, T. D. (1997). Cellular adhesion regulated p53 protein levels in primary human keratinocytes. Cancer Research 57, 3635-3639
150. Nomoto, S., Haruki, K, Kondo, M., Konishi, H., Takahashi, T., Takahashi, T. and Taka-Hashi, T. (1998). Search for mutations and examination of allelic expression imbalance of the p73 gene at 1 p36. 33 in human lung cancers. Cancer Research 58, 1380-1383
151. Nunez, G., Benedict, M. A., Hu, Y. and Inohara, N. (1998). Caspases: the proteases of the apoptotic pathway. Oncogene 17, 3237-3245
152. O'Connor, P. M., Jackman, J., Jondle, D., Bhatia, K., Magrath, F. and Kohn, K. W. (1993). Role of die p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma ceil lines. Cancer Research 53, 4776-4780
153. Okamoto, K. and Beach, D. (1994). Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO Journal 13, 4816-4822
154. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L. and Vogelstein, B. (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358, 80-83
155. Oltvai, Z. N., Milliman, C. L. and Korsmeyer, S. J. (1993). Bcl-2 heterodimerizes in vivo with a conserved homoiog, Bax, that accelerates programmed cell death. Cell 74, 609-619
156. O'Rourke, R. W., Miller, C. W., Kato, J. -G., Simon, K. J., Chen, D. L., Dang, C. V. and Koeffler, H. P. (1990). A potential transcriptional activation element in the p53 protein. Oncogene 5, 1829-1832
157. Osada, M., Ohba, M., Kawahara, C., Ishioka, C., Kanamaru, R., Katoh, I., Ikawa, Y., Nimura, Y., Nakagawara, A., Obinata, M. and Ikawa, S. (1998). Cloning and functional analysis of human p51, which structually and functionally resembles p53. Nature Medicine 4, 839-843
158. Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W. W., Kruzel, E. and Radinsky, R. (1995). Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-I expression. Molecular and Cellular Biology 15, 3032-3040
159. Pavletich, N. P., Chambers, K. A. and Pabo, C. O. (1993). The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes & Development 7, 2556-2564
160. Pellegata, N. S., Cajot, J. F. and Stanbridge, E. J. (1995). The basic carboxy-termina! domain of human p53 is dispensable for both transcriptional regulation and inhibition of tumor cell growth. Oncogene 11, 337-349
161. Peng, C. Y., Graves, P. R., Ti-Ioma, R. S., Wu, Z., Shaw, A. S. and Piwnica-Worms, H. (1997). Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277, 1501-1505
162. Petty, R. D., Cree, I. A., Sutherland, L. A., Hunter, E. M., Lande, D. P., Preecb, P. E. and Andreottl, P. E. (1994). Expression of the p53 tumour suppressor gene product is a determinant of chemosenskivity. Biochemical and Biophysical Research Communications 199, 264-270
163. Phillips, A. C., Bates, S., Ryan, K. M., Helin, K. and Vousden, K, H. (1997). Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes & Development 11, 1853-1863
164. Pihtbnpol, J. A., Tokino, T., Thiagalingam, S., El-Deiry, W. S., Klnzler, K. W. and Vogelstein, B. (1994). Sequence-specific transcriptional activation is essential for growth suppression by p53. Proceedings of the National Academy of Sciences of the United States of America 91, 1998-2002
165. Pomerantz, J., Schreiber-Agus, N., Liegeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H. -W., Cordon-Cardo, C. and Depinho, R. (1998). The Ink4a tuinour suppressor gene product, pl9ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92, 713-723
166. Powell, S. M., Zilz, N., Beazer-Barclay, Y., Bryan, T. M., Hamilton, S. R., Thibodeau, S. N., Vogelstein, B. and Kïnzler K. W. (1992). APC mutations occur early during colorectal tumorigenesis. Nature 359, 235-237
167. Quelle, D. E., Zîndy, F., Ashmun, R. A. and Sherr, C. J. (1995). Alternative reading frames of the INK4a tumour suppressor gene encode two unrelated proteins capable of inducing ceii cycle arrest. Cell 83, 993-1000
168. Ragimov, N., Krauskopf, A., Navot, N., Rotter, V., Oren, M. and Aloni, Y. (1993). Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene 8, 1183-1193
169. Reed, J. C. (1998). Bci-2 family proteins. Oncogene 17, 3225-3236
170. Righetti, S. C., Della Torre, G., Pilotti, S., Menard, S., Ottone, F., Colnaghi, M. I., Plerotti, M. A., Lavarino, C., Cornarotti, M., Oriana, S., Boiim, S., Bresciani, G. L., Spatti, G. and Zunino, F. (1996). A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Research 56, 689-693
171. Robertson, K. D. and Jones, P. A. (1998). The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA méthylation and down-regulated by wild-type p53. Molecular and Cellular Biology 18, 6457-6473
172. Roth, J., Dobbelstein, M., Freedman, D. A., Shenk, T. and Levine, A. J. (1998). Nucleo-cytopiasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO Journal 17, 554-564
173. Sabbatini, P., Lfn, J., Levine, A. J. and White, E. (1995). Essential role for p53-mediated transcription in apoptosis but not growth suppression. Genes & Development 9, 2184-2192
174. Sager, R. (1985). Genetic suppression of tumour formation. Adv. Cancer Research 44, 43-68
175. Sah, V. P., Attardi, L. D., Mulligan, G. J., Williams, B. O., Bronson, R. T. and Jacks, T. (1995). A subset of p53-deficient embryos exhibit exencephaly. Nature Genetics 10, 175-180
176. Sakaguchi, K., Sakamoto, H., Lewis, M. S., Anderson, C. W., Erickson, J. W., Appella, E. and Xle, D. (1997). Phosphorylation of serine 392 stabilizes the tetramer formation of tumour suppressor protein p53. Biochemistry 36, 10117-10124
177. Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustîn, M., Vasilev, A., Anderson, C. W. and Appella, E. (1998). DNA damage activated p53 through a phosphorylation-acétylation cascade. Genes & Development 12, 2831-2841
178. Schendel, S. L., Montal, M. and Reed, J. C. (1998). Bcl-2 family proteins as ion-channels. Cell Death and Differentiation 5, 372-380
179. Schmieg, F. I. and Simmons, D. T. (1988). Characterization of the in vitro interaction between SV40 T antigen and p53: mapping the p53 binding site. Journal of Virology 164, 132-140
180. Selvakumaran, M., Un, H. K., Miyashita, T., Wang, H. G., Krajewski, S., Reed, J. C., Hoffman, B. and LIEBERMANN, D. (1994). Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene 9, 1791-1798
181. Sentman, C. L., Shutter, J. R., Hockenbery, D., Kanagawa, O. and Korsmeyer, S. J. (1991). Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67, 879-888
182. Serrano, M., Lee, H. -W., Chin, L., Cordon-Cardo, C., Beach, D. and Depinho, R. A. (1996). Role of the INK4a locus in tumor suppression and ceil mortality. Cell 85, 27-37
183. Shieh, S. -Y., Ikeda, M., Taya, Y. and Prives, C. (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334
184. Shimizu, S., Narita, M. and Tsujimoto, Y. (1999). Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399, 483-487
185. Shivakumar, C. V., Brown, D. R., Deb, S. and Deb, S. P. (1995). Wiid-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Molecular and Cellular Biology 15, 6785-6793
186. Siles, E., Villalobos, M., Valenzuela, M. T., Nunez, M. I., Gordon, A., Mcmillan, T. J., Pedraza, V. and Ruiz De Almodovar, J. M. (1996). Relationship between p53 status and radiosensitivity in human tumour cell lines. British Journal of Cancer 73, 581-588
187. Silìciano, J. D., Canman, C. E., Taya, Y., Sakaguchi, K., Appella, E. and Kastan, M. B. (1997). DNA damage induces phosphorylation of the amino terminus of p53. Genes & Development 11, 3471-3481
188. Smith, M. L., Chen, I. T., Zhan, Q., Bae, I., Chen, C. Y., Gilmer, T. M., Kastan, M. B., O'Connor, P. M. and Fornace, A. J. (1994). Interaction of the p53-reguiated protein Gadd45 with proliferating cell nuclear antigen. Science 266, 1376-1380
189. Soengas, M. S., Alarcon, R. M., Yoshida, H., Giaccia, A. J., Hakem, R., Mak, T. W. and Lowb, S. W. (1999). Apaf-1 andcaspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284, 156-159
190. Srivastava, S., Zou, Z., Pirollo, K., Blaitner, W. and Chang, E. H. (1990). Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348, 747-749
191. Stewart, N., Hicks, G. G., Paraskevas, F. and Mow At, M. (1995). Evidence for a second cell cycle block at G2/M by p53. Oncogene 10, 109-115
192. Stewart, Z. A., Leach, S. D. and Pietenpol, J. A. (1999). p21Wafl/c'P inhibition of cyclin E/ Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Molecular and Cellular Biology 19, 205-215
193. Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J. and Wahl, G. M. (1999). A leucine-rich nuclear export signal in thep53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO Journal 18, 1660-1672
194. Stott, F., Bates, S. A., James, M., Mcconnell, B. B., Starborg, M., Brookes, S., Palmero, I., Hara, E., Vousden, K. H. and Peters, G. (1998). The alternative product from the human CDKN2A locus, pl4ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO Journal 17, 5001-5014
195. Surh, C. D. and Sprent, J. (1994). T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 372, 100-103
196. Takahashi, H., Ichimiya, S., Nìmura, Y., Watanabe, M., Furusato, M., Wakui, S., Yatani, R., Aizawa, S. and Nakagawara, A. (1998). Mutation, ailelotyping and transcription analyses of the p73 gene in prostatic carcinomas. Cancer Research 58, 2076-2077
197. Tanaka, K., Oshimura, M., Kikuchi, R., Seki, M., Hayashi, T. and Miyaki, M. (1991). Suppression of tumorigenicity in human colon carcinoma cells by introduction of normal chromosome 5 or 18. Nature 349, 340-342
198. Thut, C. J., Chen, J. L., Klemin, R. and Tjian, R. (1995). p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 267, 100-104
199. Unger, T., Sionov, R. V., Moallem, E., Yee, C. L., Howley, P. M., Oren, M. and Haupt Y. (1999). Mutations in serines 15 and 20 of human p53 impair its apoptotic activity Oncogene 18, 3205-3212
200. Vogelstein, B. and Kinzler, K. W. (1994). Has the breast cancer gene been found. Cell 79, 1-3
201. Wada, M., Bartram, C. R., Nakamura, H., Hachiya, M., Chen, D. L., Borenstein, J., Miller, C. W., Ludwig, L., Hansen-Hagge, T. E., Ludwig, W. D., Reiter, A., Mizoguchi, H. and Koeffler, H. P. (1993). Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 82, 3163-3169
202. Wagner, A. J., Kokontis, J. M. and Hay, N. (1994). Myc-mediated apoptosis requires wildtype p53 in a manner independent of cell-cycle arrest and the ability of p53 to induce P21WAFI/CIPI Gmes & Development 8, 2817-2830
203. Wang, X. W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J. M., Wang, Z., Freidberg, E. C., Evans, M. K., Taffe, B. G., Bohr, V. A., Weeda, G., Hoeijmakers, J. H. J., Forrester, K. and Harris, C. C. (1995). p53 modulation of TFIIH-associated nucleotide excision repair activity. Nature Genetics 10, 188-195
204. Wang, Y., Reed, M., Wang, P., Stenger, J. E., Mayr, G., Anderson, M. E., Schwedes, J. F. and Tegtmeyer, P. (1993). p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes & Development 7, 2575-2586
205. Waterman, M. J., Stavridi, E. S., Waterman, J. L. and Halazonetis, T. D. (1998). ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nature Genetics 19, 175-178
206. Weber, J. D., Taylor, L. J., Roussel, M., Sherr, Cj. and Bar-Sagi, D. (1999). Nucleolar ARF sequesters Mdm2 and activates p53. Nature Cell Biology 1, 20-26
207. Weinberg, R. A. (1991). Tumour suppressor genes. Science 254, 1138-1145
208. Weinberg, R. A. (1995). The retinoblastoma protein and cell cycie control. Cell 81, 323-330
209. Wilson, W. H., Teruya-Feldstein, J., Fest, T., Harris, C., Steinberg, S. M., Jaffe, E. S. and Raffeld, M. (1997). Relationship of p53, bcl-2 and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 89, 601-609
210. Woo, R. A., Mclure, K. G., Lees-Miller, S. P., Rancourt, D. E. and Lee, P. W. K. (1998). DNA-dependent protein kinase acts upstream of p53 in response to DNA damage Nature 394, 700-704
211. Wu, G. S., Burns, T. F., Mcdonald, E. R., III, Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D. D., Zhou, J. Y., Muschel, R., Hamilton, S. R., Spinner, N. B., Markowitz S Wu, G. and El-Deiry, W. S. (1997). KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genetics 17, 141-143
212. Wu, X. and Levine, A. J. (1994). p53 and E2F-1 cooperate to mediate apoptosis. Proceedings of the National Academy of Sciences of the United States of America 91, 3602-3606
213. Wyllie, A. H., Beattie, G. J. and Hargreaves, A. D. (1981). Chromatin changes in apoptosis. Histochemical Journal 13, 681-692
214. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R. and Beach, D. (1993). p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704
215. Yang, A., Kaghad, M., Wang, Y., Gillet, E., Flemming, M. D., Dotsch, V., Andrews, N. C., Caput, D. and Mckeon, F. (1998). p63 a p53 homolog at 3q27-29, encodes multiple products widi transactivating, death inducing and dominant negative activities. Molecules and Cells 2, 305-316
216. Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bronson, R. T., Tabin, C., Sharpe, A., Caput, D., Crum, C. and Mckeon, F. (1999). p63 is essential for regenerative proliferation in limb, cranofacial and epithelial development Nature 398, 714-718
217. Yonish-Rouach, E., Resnjtzky, D., Lotem, D., Sachs, L., Kimchi, A. and Oren, M. (1991). Wild-type p53 induces apoptosis of myeloid leukaematic cells that is inhibited by interleukin-6. Nature 352, 345-347
218. Yuan, Z. M., Huang, Y., Whang, Y., Sawyers, C., Weichselbaum, R., Kharbanda, S. and Kufe, D. (1996). Role for c-Abl tyrosine kinase in growth arrest response to DNA damage Nature 382, 272-274
219. Yuan, Z. M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y. Y., Lu, H., Kharbanda, S., Weichselbaum, R. and Kufe, D. (1999). p73 is regulated by tyrosine kinase c-Abi in the apoptotic response to DNA damage. Nature 399, 814-817
220. Zeng, X., Chen, L., Jost, C. A., Maya, R., Keller, D., Wang, X., Kaelin, W. G., Oren, M., Chen, J. and Lu, H. (1999). MDM2 suppresses p73 function without promoting p73 degradation. Molecular and Cellular Biology 19, 3257-3266
221. Zhan, Q., Chen, I. T., Antjnore, M. J. and Fornace, A. J., (1998). Tumor suppressor p53 can participate in transcriptional induction of the GADD45 promoter in the absence of direct DNA binding. Molecular and Cellular Biology 18, 2768-2778
222. Zhang, Y. and Xiong, Y. (1999). Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Molecules and Cells 3, 579-591
223. Zhang, Y., Xiong, Y. and Yarbrough, W. G. (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb abd p53 tumor suppressor pathways. Cell 92, 725-734
224. Zindy, P., Eischen, C. M., Randle, D. H., Kamdo, T., Cleveland, J. L., Sherr, C. J. and Roussel, M. F. (1998). Myc signalling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes & Development 12, 2424-2433
225. Zou, H., Henzel, W. J., Liu, X., Lutschg, A. and Wang, X. (1997). Apaf-i, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90, 405-413